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Abstract
A prospective observational nationwide investigation was per-
formed from September 2005 to August 2006 to study the
epidemiology of candidaemia in Sweden. From 385 patients, 403
isolates were recovered, yielding an incidence of 4.2 cases per
100 000 inhabitants. Candida albicans was the most common
species (61%), followed by Candida glabrata (20%) and Candida
parapsilosis (9%). The rates of resistance to ﬂuconazole were  1%
in C. albicans and 6–29% in non-albicans species other than
C. glabrata and Candida krusei. Resistance to voriconazole was
rare, except for C. glabrata and C. krusei. Only three isolates had
reduced susceptibility to amphotericin B, and one had reduced
susceptibility to caspofungin.
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Introduction
Candidaemia is an emerging problem in many hospital settings.
It mainly affects patients who are already severely compro-
mised by other medical conditions, such as haematological
malignancies and major abdominal surgery. Overall mortality is
high [1], and attributable mortality has been calculated to be
approximately 15% [2]. The incidence of candidaemia has
increased during the last two decades [3,4], and varying
degrees of shift from Candida albicans to non-albicans species
have been reported [5–8], some of which are associated with
antifungal susceptibility patterns other than that of C. albicans.
Nationwide studies covering all cases of candidaemia are
rare, and we have found only three epidemiological studies
providing such complete national coverage [3,4,9]. The present
study of candidaemia in Sweden, a country with a population of
9.1 million, covers incidence and species distribution, with
special focus on antifungal susceptibility.
Materials and Methods
The study was designed as a prospective, observational
nationwide laboratory-based study that was conducted from
1 September 2005 to 31 August 2006. The investigation
involved 28 of 29 microbiological laboratories in Sweden. Part
of the study material has been used in a secondary analysis on
susceptibility to different echinocandins [10].
Cases of candidaemia were identiﬁed by the 28 participating
laboratories. Blood cultures were processed with the BacT/
Alert blood culture system (bioMerieux, Marcy l’Etoile,
France) or the Bactec blood culture system (Becton Dickinson,
Franklin Lakes, NJ, USA). An episode of candidaemia was
deﬁned as the ﬁrst blood culture positive for Candida spp.
All fungal isolates were sent to the Swedish Institute for
Communicable Disease Control (Smittskyddsinstitutet, SMI)
for conﬁrmation of species identiﬁcation and antifungal
susceptibility testing. Species identiﬁcation was based on
colony colour and morphology on chromogenic agar (CHRO-
Magar, Paris, France) and pyrosequencing of the species-
speciﬁc internal transcribed spacer sequences [10]. On the
bssis of their hospital location, the patients were categorized
as belonging to the following departments: internal medicine,
general surgery, paediatrics, intensive-care unit (ICU), or
haematology/oncology/transplantation.
Susceptibility testing was performed with the Etest (AB
bioMerieux, Solna, Sweden) with the currently available antifungal
drugs for the treatment of candidaemia: amphotericin B,
ﬂuconazole, voriconazole, and caspofungin. Susceptibility to
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the antifungal drugs was determined with clinical breakpoints
from the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [11–13]. As the EUCAST has no break-
points for caspofungin, breakpoints published by the CLSI were
used [14].
Results and Discussion
From 385 patients, 403 unique isolates were obtained. The
national incidence of candidaemia was 4.2 per 100 000
inhabitants, a ﬁgure similar to those from the other Nordic
countries, with an incidence rate of 3–9 cases per 100 000
[3,4,9,15]. The male/female ratio was 206 : 179. The distribu-
tion of species and their allocation to different age groups are
shown in Table 1. C. albicans represented more than half of
the cases, which is similar to the situation in most parts of the
world [16,17]. Candida glabrata was the second most common
species, at 20%, a percentage that is similar to those in studies
from North America and northern Europe [5,16,18]. Candida
parapsilosis was found in 9% of the cases in the present study,
as compared with frequencies of 5–6% in neighbouring
countries [4,9,15]. As in other studies, candidaemia was more
common in patients younger than 1 year or older than
60 years; C. glabrata was predominant in older patients and
C. parapsilosis in children [4,15,19].
The numbers of isolates from the departments of internal
medicine, general surgery, ICUs, paediatrics and haematolo-
gy/oncology/transplantation among those 395 which it was
possible to categorize were 74, 126, 134, 21, and 40,
respectively. Thus, two-thirds of the isolates were found in
patients admitted to surgical departments and ICUs. With
the exception of a high proportion of C. parapsilosis in the
paediatric patients, the relative distribution of Candida spp.
was almost the same in the patient groups. Even in
the haematology/oncology/transplantation wards, where the
use of ﬂuconazole is more frequent, C. albicans was respon-
sible for 50% of the infections, and the shift to more
resistant non-albicans species reported elsewhere [5–8] was
not seen.
In vitro MICs of the most frequently isolated species are
listed in Table 2. Only one isolate each of C. glabrata,
C. parapsilosis and Candida tropicalis had MICs of >1 mg/L for
amphotericin B, indicating the presence of resistance mecha-
nisms. All but two C. albicans isolates (99%) were susceptible
to ﬂuconazole. Among C. parapsilosis, Candida dubliniensis,
C. tropicalis, and Candida lusitaniae, which are usually suscepti-
ble to ﬂuconazole, six isolates (9%) had MICs higher than that
of the wild-type population, making it especially important to
perform susceptibility testing when these species are found.
The use of ﬂuconazole for the treatment of C. glabrata has
been the subject of lively debate. The EUCAST has refrained
from assigning breakpoints for C. glabrata. Recent data indicate
a worse outcome with ﬂuconazole when MICs for C. glabrata
are >16 mg/L [20]. In our study, 30% of the C. glabrata
infections would have been at risk of treatment failure if
ﬂuconazole had been used, making ﬂuconazole unsuitable for
the treatment of these infections. As expected, all Candida
krusei isolates were resistant to ﬂuconazole.
According to the EUCAST breakpoints for voriconazole, all
C. parapsilosis, C. dubliniensis and C. lusitaniae isolates were
susceptible. One C. albicans and one C. tropicalis isolate had
slightly higher MICs. According to the EUCAST, there is
insufﬁcient evidence to set clinical breakpoints for C. krusei.
For C. glabrata, current data demonstrating a correlation
between in vitro susceptibility and clinical outcome are lacking.
However, the epidemiological cut-off for C. glabrata is <1 mg/L
[13], suggesting that 17% of the isolates in this study may have
some type of resistance mechanism.
Regarding caspofungin, all isolates except for one C. tropi-
calis isolate appeared to belong to the wild-type populations.
In summary, C. albicans remains the most commonly
isolated Candida species in Sweden, irrespective of the
patient’s age or type of ward. Almost all C. albicans isolates
were susceptible to azoles. With one exception, all non-
albicans species were susceptible to echinocandins. The
echinocandins should be regarded as the empirical treatment
of choice for candidaemia in severely ill patients or in the
presence of risk factors for infection caused by non-albicans
species.
TABLE 1. The number of yeast isolates in different age
groups (years)
Species Number % <1 1–20 21–40 41–60 61–80  81
Candida
albicans
245 60.8 10 10 12 59 117 37
Candida
glabrataa
81 20.1 – 1 19 44 16
Candida
parapsilosis
36 8.9 8 6 5 5 7 5
Candida
dubliniensis
15 3.7 – 1 1 6 5 2
Candida
tropicalis
8 2 – – 1 2 4 1
Candida
lusitaniae
8 2 – – 2 3 1 2
Candida
krusei
5 1.2 1 – 1 2 1 –
Candida
pelliculosa
1 0.2 1 – – – – –
Saccharomyces
cerevisiae
1 0.2 – – – – 1 –
Geotrichum
capitatum
1 0.2 – 1 – – – –
Malassezia
pachydermatis
1 0.2 1 – – – – –
Rhodotorula
mucilaginosa
1 0.2 – – – 1 – –
Total 403 – 21 18 23 97 180 63
aDemographic data are missing for one C. glabrata isolate.
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